论文部分内容阅读
目的:探讨治疗慢性失眠的更有效、复发率更低的用药方法。方法:限时限量使用艾司唑仑加艾司西酞普兰,与单用艾司唑仑比较。采用《阿森斯失眠评定量表(AIS)》《临床疗效总评量表(CGI)》分别于入组时、入组后第30天(停药时)、入组后第45天(停药2周后)三次评定其AIS评分、疗效指数(EI)、失眠复发率。结果:研究组入组第30天AIS评分显著低于对照组(P<0.05),入组第45天非常显著低于对照组(P<0.01)。研究组入组第30天EI指数非常显著性好于对照组(P<0.01),入组第45天研究组显著好于对照组(P<0.05)。研究组停药15 d后的失眠复发率显著低于对照组(P<0.05)。结论:限时限量地使用艾司唑仑加艾司西酞普兰比单用艾司唑仑治疗慢性失眠,更为有效、安全,停药后的复发率更低。
Objective: To explore more effective treatment of chronic insomnia, lower recurrence rate of medication. METHODS: The time-limited amount of estazolam plus escitalopram, compared with estazolam alone. The “Assessments of Insomnia Scale (AIS)” and “Clinical Curative Effect Rating Scale (CGI)” were used at the time of enrollment, on the 30th day after treatment (on withdrawal), on the 45th day Week) three times to assess its AIS score, efficacy index (EI), insomnia recurrence rate. Results: The AIS score of the study group on the 30th day was significantly lower than that of the control group (P <0.05). On the 45th day, the study group was significantly lower than the control group (P <0.01). The index of EI in the study group on day 30 was significantly higher than that in the control group (P <0.01). On the 45th day, the study group was significantly better than the control group (P <0.05). The relapse rate of insomnia in study group after 15 days withdrawal was significantly lower than that in control group (P <0.05). Conclusion: It is more effective and safe to use estazolam plus escitalopram than only eszolam in the treatment of chronic insomnia for a limited time. The relapse rate after stopping is lower.